Leerink Partnrs Issues Pessimistic Outlook for INSP Earnings
Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Inspire Medical Systems in a report released on Tuesday, February 11th. Leerink Partnrs analyst M ...
What is Leerink Partnrs’ Estimate for UTHR FY2024 Earnings?
Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...
Leerink upgrades CVS Health to Outperform, sees ‘positively skewed’ reward
Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...
CVS Health upgraded to Outperform from Market Perform at Leerink
Leerink upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55.Maximize Your Portfolio with Data ...
Investment Banker Cleared to Seek Multi-Million Bonuses Against Former Boston Employer
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
Leerink lifts Inspire Medical stock target to $194, maintains rating
Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...
Fintel on MSN4d
Leerink Partners Upgrades Doximity (DOCS)
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...
FiercePharma6d
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
Investing15d
Leerink maintains Tectonic stock Outperform with $69 target
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However ...
Investing15d
Leerink raises BrightSpring Health target to $26.50, keeps Outperform
On Tuesday, BrightSpring Health shares (NASDAQ:BTSG) received a positive outlook from Leerink Partners, as the firm raised its price target on the company to $26.50, up from the previous $22.00, while ...
Investing15d
Leerink raises BrightSpring Health target to $26.50, keeps Outperform
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...